Form 4: Twist Bioscience COO Sells Shares to Cover Tax Obligations

Twist Bioscience's President and COO, Patrick John Finn, sold 229 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Patrick John Finn, President and COO of Twist Bioscience, sold 229 shares of common stock on January 3, 2025.
• The sale was executed at a price of $45.5911 per share.
• This transaction was not a discretionary trade but rather a 'sell to cover' transaction mandated by the company to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Following the transaction, Mr. Finn directly owns 274,466 shares of Twist Bioscience common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment towards the company's performance or outlook.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies. It does not indicate any change in the company's outlook or performance.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a standard practice across publicly traded companies.
• Many companies use 'sell to cover' mechanisms as part of their equity compensation plans.
• The number of shares sold is relatively small compared to the total holdings of the executive, which is typical for these types of transactions.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Twist Bioscience, stock sale, insider trading, Patrick John Finn, tax obligations, restricted stock units, equity compensation, sell to cover